-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
Recently, Jimin Trust Group announced that its self-developed new coronavirus neutralizing antibody injection (project code: JMB2002) has recently been approved by the US FDA and will start clinical trials in the United States.
At present, the development of neutralizing antibodies is also one of the important research directions against the new coronavirus.
One of the key steps for the new coronavirus to infect human cells is the receptor binding domain (RBD) of the S1 subunit of the virus surface spike protein (S protein) and the angiotensin II converting enzyme 2 (ACE2) on the surface of human cells.
Therefore, a number of neutralizing antibodies currently being developed around the world target the RBD region of the new coronavirus S protein.
According to the press release of Jimin Trust, the neutralizing antibody JMB2002 that the company is developing can accurately occupy the key epitope of the receptor binding domain (RBD) and ACE2 binding interface of the S1 subunit of the virus S protein.
It is reported that the researchers found in in vitro experiments that the binding ability of JMB2002 with the S1 protein of the mutant strain found in South Africa increased by 6.
Note: The original text has been deleted
